Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 66

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 66
---
 interest rate 
     3.82% 
     3.52% to 4.33% 

27

The classification of the fair
value of the earnout liability and derivative liabilities and the change in the fair value measurement using significant inputs (Level
3) for the nine months ended September 30, 2025 (Successor), for the period from January 1, 2024 through February 13, 2024 (Predecessor),
for the three months ended September 30, 2024 (Successor), and for the period from February 14, 2024 through September 30, 2024 (Successor)
for the Company is presented below:

    Level 1  
    Level 2  
    Level 3  
    Total 
  
    Preferred stock warrant liability (Predecessor): 

    Balance at December 31, 2023 
    $-  
    $-  
    $320,117  
     320,117 
  
    Reclassification of warrant liability to equity 
     -  
     -  
     (320,117) 
     (320,117)
  
    Balance at February 13, 2024 
    $-  
    $-  
    $-  
    $- 

    Earnout liability (Successor): 

    Balance at June 30, 2024 
    $-  
    $-  
    $200,000  
    $200,000 
  
    Gain on revaluation of earnout liability 
     -  
     -  
     (170,000) 
     (170,000)
  
    Balance at September 30, 2024 
    $-  
    $-  
    $30,000  
    $30,000 

    Earnout liability (Successor): 

    Balance at February 14, 2024 
    $-  
    $-  
    $4,900,000  
    $4,900,000 
  
    Gain on revaluation of earnout liability 
     -  
     -  
     (4,870,000) 
     (4,870,000)
  
    Balance at September 30, 2024 
    $-  
    $-  
    $30,000